Table 3.
Reported Antiretroviral Therapy Regimens of HOPE Donors at Donation
| ART Regimen | Donors, No. (n = 37) |
|---|---|
| 2 NRTIs + INSTI | 24 (65%) |
| TAF/FTC/EVG/c | 9 |
| ABC/3TC/DTG | 7 |
| TAF/FTC/BIC | 5 |
| TAF/FTC + DTG | 2 |
| TDF/FTC/EVG/c | 1 |
| 2 NRTIs + NNRTI | 4 (11%) |
| TAF/FTC/RPV | 3 |
| TDF/FTC + ETR | 1 |
| 2 NRTIs + PI | 3 (8%) |
| TAF/FTC + ATV/c | 1 |
| TDF/FTC + ATV/c | 1 |
| TDF/FTC + DRV/c | 1 |
| Other | 6 (16%) |
| FTC + DTG | 1 |
| 3TC + DTG + DRV/r | 1 |
| TDF/FTC + DTG + ATV/r | 1 |
| ABC/3TC + TDF + DRV/c | 1 |
| d4t + TAF/FTC + DTG + DRV/c | 1 |
| TDF/FTC/EFV + DRV/r | 1 |
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; ATV, atazanavir; BIC, bictegravir; c, cobicistat; d4t, stavudine; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ETR, etravirine; EVG, elvitegravir; FTC, emtricitabine; HOPE, HIV Organ Policy Equity; INSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; r, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.